Controversies in Alzheimer's Drug Approval

This chapter examines the rapid approval of an Alzheimer's drug amidst concerns of inadequate evidence and potential regulatory collusion. It critiques the implications of high pricing and the U.S. healthcare system's inability to negotiate drug costs, highlighting the need for stronger advocacy for evidence-backed medications.